{
  "abstract": "Background: Tuberculosis (TB) preventive treatment (TPT) is a core component of TB control. Levofloxacin was recently recommended by the World Health Organization as TPT in children exposed to multidrug-resistant tuberculosis (MDR-TB). However, the affordability and feasibility of TPT provision for governments, health services, individual households and global donors is uncertain. Methods: This costing analysis used empirical data collected alongside the TB-CHAMP clinical trial which investigated levofloxacin TPT in children exposed to MDR-TB in South Africa. We modelled the societal (health system and household) cost of levofloxacin TPT, other potential future (but not currently recommended) MDR-TB exposure TPT options and compared with drug-susceptible TPT options in children and adolescents under 15 years old. We modelled costs across 12 different medicine and formulation options for 11 paediatric dosing weight-bands using TB-CHAMP and household survey data, with national and international procurement medicine pricing. Results: Total societal costs of providing levofloxacin TPT and its monitoring per child were US$252 (0- < 5 years) and US$256 (5- < 15-years) and had comparable costs to drug-susceptible TPT regimens when using Global Drug Facility pricing. Pharmaceutical costs for a course of TPT using child-friendly formulations in children <5 years varied between US$38 (levofloxacin), US$80 (bedaquiline) and US$582 (delamanid). Household costs associated with accessing TPT and ongoing monitoring ranged from 1.6%−2.1% of median annual income of affected households, with shorter TPT courses incurring lower household costs. Global Drug Facility procurement achieved TPT pricing at 70% of the costs of national South African procurement, and enabled access to a wider range of child-friendly formulations. Discussion: Costs of TPT are influenced by factors including medicine pricing and procurement, the use of child-friendly formulations, implementation approach, the duration of treatment, and choice of TPT regimen across weight and age distributions. Costs to households are relatively small but may be significant for impoverished households already managing the financial disruption of a family member with MDR-TB disease.",
  "abstract_shown": true,
  "affiliations": [
    "Health Economics Unit, School of Public Health, University of Cape Town, Cape Town, South Africa",
    "Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town, South Africa",
    "Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa",
    "Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom",
    "Wits Research Health Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa",
    "THINK, THINK South Africa, Durban, South Africa",
    "Perinatal HIV Research Unit (PHRU) and Infectious Diseases and Oncology Research Institute, University of Witwatersrand, Johannesburg, South Africa",
    "Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, United States of America",
    "Department of Infectious Disease, Imperial College London, London, United Kingdom"
  ],
  "article_type": "Research Article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Thomas Wilkinson"
    },
    {
      "affs": [
        1
      ],
      "name": "Suereta Fortuin"
    },
    {
      "affs": [
        2
      ],
      "name": "Anneke C. Hesseling"
    },
    {
      "affs": [
        3
      ],
      "name": "H. Simon Schaaf"
    },
    {
      "affs": [
        4
      ],
      "name": "Trinh Duong"
    },
    {
      "affs": [
        5
      ],
      "name": "Diana M. Gibb"
    },
    {
      "affs": [
        6
      ],
      "name": "Susan E. Purchase"
    },
    {
      "affs": [
        7
      ],
      "name": "Lee Fairlie"
    },
    {
      "affs": [
        8
      ],
      "name": "Suzanne Staples"
    },
    {
      "name": "Neil Martinson"
    },
    {
      "name": "Edina Sinanovic"
    },
    {
      "name": "James A. Seddon"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2fe750k795pjh.bib",
  "cited_by": 0,
  "doi": "10.1371/journal.pone.0336561",
  "fulltext_url": null,
  "id": "2fe750k795pjh",
  "issns": [
    "1932-6203"
  ],
  "landing_url": "https://doi.org/10.1371/journal.pone.0336561",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2725|Tuberculosis Research and Epidemiology"
    ],
    [
      "plos",
      "/Biology and life sciences/Physiology/Physiological parameters/Body weight"
    ],
    [
      "plos",
      "/Medicine and health sciences/Health care/Health economics/Pharmacoeconomics/Drug prices"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Infectious diseases/Bacterial diseases/Tuberculosis"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Infectious diseases/Bacterial diseases/Tuberculosis/Multi-drug-resistant tuberculosis"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Tropical diseases/Tuberculosis"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Tropical diseases/Tuberculosis/Multi-drug-resistant tuberculosis"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pharmacology/Drugs/Isoniazid"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pharmacology/Pharmacoeconomics/Drug prices"
    ],
    [
      "plos",
      "/People and places/Geographical locations/Africa/South Africa"
    ],
    [
      "plos",
      "/Research and analysis methods/Research design/Clinical research design/Adverse events"
    ],
    [
      "plos",
      "/Social sciences/Economics/Commerce/Procurement"
    ],
    [
      "plos",
      "/Social sciences/Economics/Health economics/Pharmacoeconomics/Drug prices"
    ]
  ],
  "openalex": "W7220926054",
  "pdf_url": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0336561&type=printable",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-08",
  "publisher": "Public Library of Science",
  "ris": "https://research.draconitic.com/paper/2fe750k795pjh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:30Z",
      "native_id": "10.1371/journal.pone.0336561",
      "source": "plos",
      "url": "https://doi.org/10.1371/journal.pone.0336561"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "plos:infectious diseases",
      "subfield": "infectious-disease"
    },
    {
      "field": "medicine",
      "origin": "plos:pharmacology",
      "subfield": "pharmacology-toxicology"
    },
    {
      "field": "medicine",
      "origin": "plos:physiology",
      "subfield": "physiology"
    }
  ],
  "title": "Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa",
  "title_text": "Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:30Z",
  "url": "https://research.draconitic.com/paper/2fe750k795pjh",
  "venue": "PLOS One",
  "versions": []
}